

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/698,099		
		Filing Date	October 31, 2003		
		First Named Inventor	Schenk, Dale B.		
		Art Unit	1648		
		Examiner Name	Michelle S. Homing		
Sheet	1	of	4	Attorney Docket Number	015270-008930US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	239	US 5,807,741	09-15-1998	Brown et al.	
	219	US-5,753,624	05-19-1998	McMichael	

U.S. PATENT APPLICATIONS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	214	US-11/894,772	08-20-2007	Schenk et al.	
	215	US-11/894,744	08-20-2007	Schenk et al.	
	216	US-11/894,605	08-20-2007	Schenk et al.	
	217	US-11/842,054	08-20-2007	Schenk et al.	
	218	US-11/841,996	08-20-2007	Schenk et al.	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	227	WO	01/60794	A2	08-23-2001	University of California		
	228	WO	01/60794	A3	08-23-2001	University of California		
	220	WO	03/045128	A2	06-05-2003	New York University		
	221	WO	03/045128	A3	06-05-2003	New York University		
	235	WO	03/000714	A2	01-03-2003	New York University		
	236	WO	03/000714	A3	01-03-2003	New York University		
	222	WO	08/103472	A2	08-28-2008	Elan Pharmaceuticals, Inc. et al.		

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP § 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/698,099
		Filing Date	October 31, 2003
		First Named Inventor	Schenk, Dale B.
		Art Unit	1648
		Examiner Name	Michelle S. Homing
Sheet	2	of	4
		Attorney Docket Number	015270-008930US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	226	ANDERSON et al., "Phosphorylation of SER-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease," <i>The Journal of Biological Chemistry</i> , 281:29739-29752 (2006).	<input type="checkbox"/>
	240	Alves da Costa, "Recent Advances on α -Synuclein Cell Biology : Functions and Dysfunctions," <i>Current Molecular Medicines</i> , 3:17-24 (2003).	<input type="checkbox"/>
	241	CASADESUS et al., "The Estrogen Myth; Potential Use of Gonadotropin-releasing hormone Agonists for Treatment of Alzheimer's Disease," <i>Drugs R&D</i> , 7(3):187-193 (2006).	<input type="checkbox"/>
	224	CHILCOTE et al., "Comparison of alpha-synuclein species in Lewy bodies and the soluble fraction of diffuse Lewy body disease brain," <i>Database Biosis [Online] Biosciences Information Service</i> , Philadelphia, PA, US (2003) Abstract only.	<input type="checkbox"/>
	83	CLELAND et al., "Isomerization and Formulation Stability of the Vaccine Adjuvant QS-21," <i>J. of Pharm Sci.</i> , 85(1): 22-28 (1996).	<input type="checkbox"/>
	87	DEMATOS et al., "Peripheral Anti A β Antibody Alters CNS And Plasma A β Clearance and Decreases Brain A β Burden in a Mouse Model of Alzheimer's Disease," published online before print July 3, 2001 at 10.1073/pnas.151261398; <i>PNAS</i> , 98(15):8850-8855 (2001).	<input type="checkbox"/>
	237	EP 03783083.3 European Supplementary Search Report completed 10/10/2008.	<input type="checkbox"/>
	238	EP 05814041.9 European Supplementary Search Report completed 10/29/2008.	<input type="checkbox"/>
	104	FRIEDLAND et al., "Development of an anti-A β monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer's disease," <i>Mol. Neurology</i> , 9:107-113 (1994).	<input type="checkbox"/>
	242	JANEWAY et al., <i>Immunology</i> , 3 rd edition, 8:18-8:19 (1997).	<input type="checkbox"/>
	229	HASHIMOTO et al., "B-synuclein inhibits [alpha]-synuclein aggregation: A possible role as an anti-Parkinsonian factor", <i>NEURON</i> , 32(2):213-223 (2001).	<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/698,099
				Filing Date	October 31, 2003
				First Named Inventor	Schenk, Dale B.
				Art Unit	1648
				Examiner Name	Michelle S. Horning
Sheet	3	of	4	Attorney Docket Number	015270-008930US

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
	233	HEISER et al., "Inhibition of huntingin fibrillogenesis by specific antibodies and small molecules: Implications for Huntington's disease therapy," Proceedings of the National Academy of Sciences of USA, 97(12):6739-6744 (2000), Abstract only.	<input type="checkbox"/>		
	232	LECERF et al., "Human single-chain Fv intrabodies counteract in situ huntingin aggregation in cellular models of Huntington's disease," Proceeding of the National Academy of Sciences of USA, 98(8):4764-4769 (2001).	<input type="checkbox"/>		
	126	LEE et al., "Human α -synuclein-harboring familial Parkinson's disease-linked Ala-53 \rightarrow Thr mutation causes neurodegenerative disease with α -synuclein aggregation in transgenic mice," PNAS, 99:8968-8973 (2002).	<input type="checkbox"/>		
	225	LEE et al., "Truncated alpha-synuclein is generated in vivo and potentiates alpha synuclein aggregation," Database Biosis [Online] Biosciences Information Service, Philadelphia, PA, US (2003), Abstract only.	<input type="checkbox"/>		
	243	PERRIN et al., "Epitope mapping and specificity of the anti- α -synuclein monoclonal antibody Syn-1 in mouse brain and cultured cell lines," <u>Neuroscience Letters</u> , 349:1331-1335 (2003), abstract only.	<input type="checkbox"/>		
	234	ROCHET et al., "Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse α -synuclein" <u>Biochemistry</u> , 39(35):10619-10626 (2000), abstract only.	<input type="checkbox"/>		
	244	SIDU et al., "Does α -synuclein modulate dopaminergic synaptic content and tone at the synapse," FASEB, 18:637-647 (2004).	<input type="checkbox"/>		
	245	SPILLANTINI et al., " α -Synuclein in Lewy bodies," <u>Nature</u> , 388:839-840 (1997).	<input type="checkbox"/>		
	246	TAKEDA et al., "Abnormal Accumulation of NACP/ α -Synuclein in Neurodegenerative Disorders," <u>American Journal of Pathology</u> , 152:367-372 (1998).	<input type="checkbox"/>		
	247	TOFARIS et al., "Physiological and Pathological Properties of α -synuclein," <u>Cellular and Molecular Life Sciences</u> , pp. 1-8 (2007).	<input type="checkbox"/>		
	223	TOFARIS et al., "Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function," <u>The Journal of Biological Chemistry</u> , 278: 44405-44411 (2003).	<input type="checkbox"/>		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete If Known	
				Application Number	10/698,099
				Filing Date	October 31, 2003
				First Named Inventor	Schenk, Dale B.
				Art Unit	1648
				Examiner Name	Michelle S. Horning
Sheet	4	of	4	Attorney Docket Number	015270-008930US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	231	WANKER, "Protein aggregation in Huntington's and Parkinson's disease: Implications or therapy," Molecular Medicine Today 2000 GB, 6(10):387-397 (2000), Abstract only.	<input type="checkbox"/>	
	230	WINDISCH et al., "Development of a new treatment for Alzheimer's disease and Parkinson's disease using anti-aggregatory [beta]-synuclein-derived peptides," Journal of Molecular Neuroscience, 19(2): 63-69 (2002) abstract only.	<input type="checkbox"/>	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.